Prophylactic Anticonvulsant Therapy in Hypertensive Crises of Pregnancy—The Need for a Large, Randomized Trial

Moodley, Jagidesa; Moodley, Vadi

doi:10.3109/10641959409072226

Cited by 53 publications

(36 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 HELLP syndrome was observed in the present study in 4.21% women with severe preeclampsia which was lower than that observed in study of Moodley and Moodley and Dayicioglu et al that was 8% and 7.7% respectively. 5,6 In patients with severe preeclampsia received Magnesium sulfate prophylaxis, incidence of eclampsia was 4.49% and it was comparable to that observed by Dayicioglu et al in their study, which was 3.62%. 6 Reti, Girard et al and Singh et al in their studies of severe preeclampsia treated with magnesium sulfate did not notice eclampsia in their patients.…”

Section: Comparison Of Associated Pregnancy Complicationsupporting

confidence: 75%

“…The mean age was less than that observed in the studies of Moodley and Moodley, Magpie trial and Dayicioglu et al 2,5,6 This variation in the mean age may be explained by the early marriage and early onset of reproductive life in India. In non-severe preeclampsia group the mean age in our study is comparable to that observed in the study of Livingston et al 7 The percentage of primigravidae in the present study was 64.61%, and is comparable to that observed in study of Atkinson et al 4 The mean gestational age of patients in study and control group was respectively 38.38 and 38.09 weeks which was comparable to that observed in the randomized control trial in women with mild preeclampsia by Livingston et al…”

contrasting

confidence: 45%

“…In severe preeclampsia, perinatal death was 23.35% which was comparable to 20.22% as observed by Sardesai et al, the perinatal mortality was 20.10% in the study of Dayicioglu et al and 17.09% as observed by Moodley and Moodley. 1,5,6 …”

Section: Comparison Of Labour Characteristics and Perinatal Outcomementioning

confidence: 99%

See 2 more Smart Citations

Study of role of Magnesium sulfate in prevention of eclampsia

Gadappa

Dixit

2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Hypertensive disorders of pregnancy have a clinical spectrum ranging from non-severe to severe preeclampsia and then potentially to eclampsia. Magnesium sulfate is drug of choice for women with eclampsia and now adapted for prophylaxis of seizures in women with preeclampsia. Methods: It is randomized clinical trial, including 876 patients with preeclampsia fulfilling inclusion criteria. Patients with severe preeclampsia received anticonvulsant prophylaxis with magnesium sulfate. Patients with non-severe preeclampsia were randomized in two groups study group and control group. Patients in study group had received anticonvulsant prophylaxis with magnesium sulfate. The data obtained was analyzed with respect to maternal and perinatal outcome, severity of disease progression and adverse reactions of magnesium sulphate in each group. Results: In this study statistically, significant difference was seen with respect to severity of disease progression and incidence of eclampsia among study and control group. Conclusions: Administration of Magnesium sulfate in patients with non-severe preeclampsia does not affect the progress of labour or perinatal outcome, on contrary it improves maternal outcome by reducing incidence of eclampsia and progression of disease, without significant side effect of drug.

show abstract

Section: Comparison Of Associated Pregnancy Complicationsupporting

confidence: 75%

contrasting

confidence: 45%

See 1 more Smart Citation

Study of role of Magnesium sulfate in prevention of eclampsia

Gadappa

Dixit

2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

show abstract

“…• Le Magpie Trial [5] [5,6,26,27] jugée sur le taux d'Apgar inférieur à sept à cinq minutes, la détresse respiratoire, le besoin d'intubation, l'hypotonie, ou la durée de séjours en unité de soins intensifs.…”

unclassified

“…Le rapport bénéfices/risques n'est donc pas en faveur de la prophylaxie par le sulfate de magnésium en cas de prééclampsie modérée. • Le taux de convulsions parmi les femmes ayant une prééclampsie sévère ne recevant pas de sulfate de magné-sium est 2,0 %, tandis qu'il est de 0,6 % sous sulfate de magnésium [5,6,26,27]. Ainsi, 71 femmes ayant une préé-clampsie sévère doivent être traitées pour éviter un cas d'éclampsie.…”

unclassified